12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ganetespib: Additional Phase IIb data

Additional interim data from 252 patients with stage IIIB/IV NSCLC adenocarcinoma in the open-label Phase IIb portion of the international Phase IIb/III GALAXY-1 trial showed that ganetespib plus docetaxel as second-line treatment led to a median OS, a secondary endpoint, of 9.8 vs. 7.4 months in patients receiving docetaxel alone (unadjusted HR=0.82, p=0.082). A pre-specified Cox regression analysis that was used to assess and adjust for potential imbalances in prognostic factors led to an OS HR of 0.73 (p=0.041). Synta said the unadjusted analysis was the primary analysis specified in the trial's protocol. In patients who were enrolled in the trial >6 months after diagnosis...

Read the full 502 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >